English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/209443
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis

AuthorsCalvo-Barreiro, Laura; Eixarch, Herena; Ponce-Alonso, Manuel; Castillo, Mireia; Lebrón-Galán, Rafael; Mestre, Leyre ; Guaza, Carmen ; Clemente, Diego; del Campo, Rosa; Montalban, Xavier; Espejo, Carmen
Issue Date7-Apr-2020
PublisherMultidisciplinary Digital Publishing Institute
CitationCells 9 (4): 906 (2020)
AbstractPrevious studies in experimental autoimmune encephalomyelitis (EAE) models have shown that some probiotic bacteria beneficially impact the development of this experimental disease. Here, we tested the therapeutic effect of two commercial multispecies probiotics—Lactibiane iki and Vivomixx—on the clinical outcome of established EAE. Lactibiane iki improves EAE clinical outcome in a dose-dependent manner and decreases central nervous system (CNS) demyelination and inflammation. This clinical improvement is related to the inhibition of pro-inflammatory and the stimulation of immunoregulatory mechanisms in the periphery. Moreover, both probiotics modulate the number and phenotype of dendritic cells (DCs). Specifically, Lactibiane iki promotes an immature, tolerogenic phenotype of DCs that can directly induce immune tolerance in the periphery, while Vivomixx decreases the percentage of DCs expressing co-stimulatory molecules. Finally, gut microbiome analysis reveals an altered microbiome composition related to clinical condition and disease progression. This is the first preclinical assay that demonstrates that a commercial probiotic performs a beneficial and dose-dependent effect in EAE mice and one of the few that demonstrates a therapeutic effect once the experimental disease is established. Because this probiotic is already available for clinical trials, further studies are being planned to explore its therapeutic potential in multiple sclerosis patients.
URIhttp://hdl.handle.net/10261/209443
Identifiersdoi: 10.3390/cells9040906
Appears in Collections:Colección MDPI
Files in This Item:
File Description SizeFormat 
cells-09-00906.pdf4,23 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.